LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

Search

AxoGen Inc

Fechado

SetorSaúde

23.51 0.26

Visão Geral

Variação de preço das ações

24h

Atual

Mín

22.99

Máximo

23.98

Indicadores-chave

By Trading Economics

Rendimento

129K

708K

Vendas

3.4M

60M

EPS

0.12

Margem de lucro

1.178

Funcionários

451

EBITDA

-181K

4.2M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+13.96% upside

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

289M

1.1B

Abertura anterior

23.25

Fecho anterior

23.51

Sentimento de Notícias

By Acuity

17%

83%

25 / 374 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

AxoGen Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

25 de ago. de 2025, 11:48 UTC

Grandes Movimentos do Mercado

Axogen Shares Fall Premarket as FDA Extends Avance Review

Comparação entre Pares

Variação de preço

AxoGen Inc Previsão

Preço-alvo

By TipRanks

13.96% parte superior

Previsão para 12 meses

Média 26.86 USD  13.96%

Máximo 34 USD

Mínimo 20 USD

Com base em 7 analistas de Wall Street que oferecem metas de preço de 12 meses para AxoGen Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

7 ratings

7

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

N/A / 14.4Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Neutral Evidence

Sentimento

By Acuity

25 / 374 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre AxoGen Inc

Axogen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. Axogen, Inc. is headquartered in Alachua, Florida.
help-icon Live chat